- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04225728
Evaluation on Performance and Oxydative Stress in Patient With Iron deficIency and Stable Heart Failure Study (ERADAL-HF)
Rationale and Design of Ferric Polymaltose Hydroxide and Iron Sucrose Evaluation on Performance and Oxydative Stress in Patient With Iron deficIency and Stable Heart Failure Study
ERADAL-HF is a double blinded, multi-centre, prospective, randomized, three arm study, enrolled ambulatory patients with chronic heart failure [New York Heart Association (NYHA) class II/III], with iron deficiency [defined as ferritin <100 ng/mL, or ferritin 100-300 ng/mL if transferrin saturation (TSAT) <20%] and haemoglobin (Hb) < 15 g/dL. Patients were randomized 1:1:1 to treatment into three arms: a first group treated with intravenous iron supplementation, a second treated by intramuscular iron supplementation and the third one which have received placebo. These patients were followed-up during a period of 04 weeks.
The aim of this study is to assess the short term effect of parenteral iron supplementation on exercise tolerance and oxidative stress in patients with stable chronic heart failure and iron deficiency
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
ERADAL-HF is a double blinded, multi-centre, prospective, randomized, three arm study, enrolled ambulatory patients with chronic heart failure [New York Heart Association (NYHA) class II/III], with iron deficiency [defined as ferritin <100 ng/mL, or ferritin 100-300 ng/mL if transferrin saturation (TSAT) <20%] and haemoglobin (Hb) < 15 g/dL. Patients were randomized 1:1:1 to treatment into three arms: a first group treated with intravenous iron supplementation, a second treated by intramuscular iron supplementation and the third one which have received placebo. These patients were followed-up during a period of 04 weeks.
The aim of this study is to assess the short term effect of parenteral iron supplementation on exercise tolerance and oxidative stress in patients with stable chronic heart failure and iron deficiency in a sub-Saharan Africa. In addition, it will also try to evaluate its effectiveness using the intramuscular route and this with a simplified administration scheme.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Yaoundé, Cameroon
- Yaounde Central Hospital, Cardiology department
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subjects with stable CHF (NYHA II/III functional class)
- Screening serum ferritin <100 ng/mL or 100-300 ng/mL with transferrin saturation <20%.
- Haemoglobin < 15 g/dl ;
- On optimal background therapy (as determined by the investigator) for at least 4 weeks with no dose changes of heart failure drugs during the last 2 weeks (with the exception of diuretics). In general, optimal pharmacological treatment should include an angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker and a beta blocker unless contraindicated or not tolerated and diuretic if indicated.
- Subject must be capable of completing the 6MWT
- Before any study-specific procedure, the appropriate written informed consent must be obtained.
Exclusion Criteria:
- Subject has known sensitivity to any of the products to be administered during dosing.
- History of acquired iron overload.
- History of erythropoietin-stimulating agent, i.v. iron therapy, and/or blood transfusion in previous 6 weeks prior to randomization.
- Oral iron therapy at doses >100 mg/day in previous 1 week prior to randomization. Note: ongoing use of multivitamins containing iron <75 mg/day is permitted.
- Body weight ≤35 kg.
- Exercise training programme(s) in the 3 months prior to screening or planned in the next 6 months.
- Chronic liver disease (including active hepatitis) and/or screening alanine transaminase or aspartate transaminase above three times the upper limit of the normal range
- Subject will not be available for all protocol-specified assessments.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: Iron sucrose IV arm
Perfusion of diluted iron sucrose i.v. in two weeks.
Half of the total dose at Day 0 and the other half at Day 14
|
Intervention will consisted of the administration for the IV route. -The IV route in two doses will be diluted bolus injection of iron or normal saline at day 0 and day 14.
Other Names:
|
ACTIVE_COMPARATOR: Ferric polymaltose hydroxide complex IM arm
Injection in two series, begin at Day 0 and the second at Day 14.
In each series, we administered 300 mg of iron IM until reach half of the dose
|
Intervention will consisted of the administration for the IM route.
Drug will be given in two series of injection; the first series will began at day 0 and consist of administration of 300 mg of iron per day in intramuscular injection up to the half of the total dose and the second series will began at day 14 for the administration of the other half with the same scheme than the first.
Other Names:
|
PLACEBO_COMPARATOR: Placebo arm
100 ml i.v. of normal saline administered at Day 0 and at day 14.
|
100 ml i.v. of normal saline administered at Day 0 and at day 14.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Variation in 6-minute walk test (6MWT) distance
Time Frame: 4 weeks
|
Variation in 6MWT in meter distance from the baseline to week 4.
By using pedometer
|
4 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in quality of life assessed by the Minnesota Living With Heart Failure Questionnaire (MLWHFQ)
Time Frame: 4 weeks
|
Minnesota Living With Heart Failure Questionnaire score at Week 4 adjusted for baseline
|
4 weeks
|
Change in serum ferritin concentration
Time Frame: 4 weeks
|
Change in serum ferritin concentration (micromol/l) level from baseline to week 4.
By immunology
|
4 weeks
|
Change in serum concentration of anti-oxidant markers: Reduced Glutathione (micromol)
Time Frame: 4 weeks
|
Change in serum concentration of anti-oxidant markers from baseline to week 4.
By spectrophotometer
|
4 weeks
|
Change in serum concentration of oxidant marker: Malondialdehyde (micromol/l)
Time Frame: 4 weeks
|
Change in concentration of oxidant marker from baseline to week 4.
By spectrophotometer
|
4 weeks
|
Change in Left Ventricle Ejection Fraction by Simpson method
Time Frame: 4 weeks
|
Change in Left Ventricle Ejection Fraction (%) by Simpson method on echocardiography from baseline to week 4
|
4 weeks
|
Cost-effectiveness by using the Incremental Cost-effectiveness Ratio (ICER)
Time Frame: 4 weeks
|
Cost-effectiveness by using the ICER questionnaire between the IV and the IM route
|
4 weeks
|
Standard safety assessments
Time Frame: 4 weeks
|
Standard safety assessments: adverse events by questionnaires
|
4 weeks
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ERADAL-HF
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Iron Deficiency
-
Pennington Biomedical Research CenterRecruitingIron-deficiency | Iron Deficiency Anemia | Iron Deficiency Anemia TreatmentUnited States
-
King's CollegeCompletedIron-deficiency | Iron Deficiency Anemia | Iron Deficiency (Without Anemia)United States
-
Children's Hospital Los AngelesNot yet recruitingAnemia | Iron Deficiency Anemia | Anemia, Iron Deficiency | IDA - Iron Deficiency AnemiaUnited States
-
Swiss Federal Institute of TechnologyUnited States Agency for International Development (USAID); Quadram Institute... and other collaboratorsCompletedIron-deficiency | Iron Deficiency Anemia | Iron Deficiency (Without Anemia)Peru
-
Arrowhead Regional Medical CenterRecruitingIron Deficiency Anemia of PregnancyUnited States
-
Iowa State UniversityCompletedIron-deficiency | Bioavailability | Anemia, Iron Deficiency | Absorption; Iron | Serum IronUnited States
-
Société des Produits Nestlé (SPN)CompletedIron-deficiency | Anemia | Iron Deficiency AnemiaPhilippines
-
Swiss Federal Institute of TechnologyUniversity of MalawiCompletedIron-deficiency | Iron Deficiency AnemiaMalawi, Switzerland
-
Johann Wolfgang Goethe University HospitalLudwig-Maximilians - University of MunichCompletedNon-invasive Diagnostics of Iron Deficiency in Surgical Patients by Measuring Zinc Protoporphyrin-IXIron-deficiency | Anemia | Iron Deficiency AnemiaGermany
-
Kansas State UniversityUnited States Department of Agriculture Foreign Agricultural Service; American...CompletedIron-deficiency | Iron Deficiency AnemiaUnited States
Clinical Trials on Iron Sucrose IV
-
Xinhua Hospital, Shanghai Jiao Tong University...Completed
-
Peking Union Medical College HospitalUnknownAnemia, Iron DeficiencyChina
-
Richard FedorakCompletedIron Deficiency | Inflammatory Bowel DiseaseCanada
-
University of SaskatchewanNot yet recruitingAnaemia in Ovarian CarcinomaCanada
-
Anemia Working Group RomaniaWithdrawnAnemia | Chronic Kidney Disease | Chronic Heart FailureRomania
-
HaEmek Medical Center, IsraelWithdrawn
-
University of OxfordNational Center of Cardiology and Internal Medicine named after academician...WithdrawnHypertension, PulmonaryKyrgyzstan
-
Vifor Fresenius Medical Care Renal PharmaWorldwide Clinical Trials; Fresenius Medical Care Deutschland GmbHTerminatedAnemia | End Stage Renal DiseaseUnited Kingdom
-
Saskatchewan Health Authority - Regina AreaSaskatchewan Centre for Patient-Oriented ResearchRecruitingIron Deficiency Anaemia in ChildbirthCanada
-
University of OxfordCompleted